CAR T-cell Therapy

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

Although CD19 has proved to be an attractive and effective target for chimeric antigen receptor T-cell therapies in hematologic malignancies, a significant subset of patients treated with this groundbreaking form of immunotherapy eventually relapse.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Nina Shah, MD, discusses the present and future of chimeric antigen receptor T-cell therapy in myeloma.

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of CAR T-cell therapy in multiple myeloma.

Brian Till, MD, discusses the rapidly evolving field of chimeric antigen receptor (CAR) T cells.

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Abhinav Deol, MD, discusses the basics of chimeric antigen receptor T-cell therapy, potential new directions for these products, and the possible impact new products might have on the field.

Eric Smith, MD, PhD, discusses the development of novel CAR T-cell therapies for patients with multiple myeloma.

Deepu Madduri, MD, discusses the role of CAR T-cell therapy and other novel treatment options for patients with relapsed/refractory multiple myeloma.

While clinical trial findings with chimeric antigen receptor (CAR) T-cell therapy have impacted the landscape of pediatric acute lymphoblastic leukemia, additional CAR T-cell products continue to be investigated.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

Frederick L. Locke, MD, discusses the expansion of CAR T-cell therapy in patients with lymphomas following the 2017 approval of axicabtagene ciloleucel and remaining research questions with the therapy.

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

David G. Maloney, MD, PhD, reviews the latest developments with chimeric antigen receptor T-cell therapy in patients with non-Hodgkin lymphoma.

The European Commission has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.